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Background: Diabetes is a leading risk factor for impaired kidney function, an indicator 
of chronic kidney disease. The aim of this study was to examine the association between 
type 2 diabetes (T2D) and impaired kidney function among adults in sub-Saharan Africa 
(SSA).
Methods: Participants were enrolled from Ghana, Kenya, and Nigeria. Impaired kidney 
function was based on an estimated glomerular filtration rate <60 ml/min/1.73 m2. Using 
logistic regression models, we conducted case–control analyses to estimate the multi-
variate-adjusted association of T2D and kidney function.
results: We used data from 4815 participants for whom the mean (SD) age was 48 
(15) years, 41% were male and 46% had T2D. Those with T2D were more likely to 
have impaired kidney function [13.4% (95% CI: 11.9–14.7)] compared to those without 
T2D [4.8% (95% CI: 4.0–5.6)], p-value <0.001. The multivariate odds ratio of impaired 
kidney function among those with type 2 diabetes was 1.50 (95% CI: 1.17–1.91) 
p-value = 0.001, compared to those without T2D. Also, individuals with T2D who were at 
least 60 years old, obese, hypertensive or dyslipidemic were more likely to have impaired 
kidney function compared to those without T2D.
conclusion: T2D was associated with 50% increased risk of impaired kidney function in 
this sample of adults from SSA. Interventions targeted at prevention, early diagnosis, and 
management of T2D are likely to reduce the burden of kidney disease in SSA.
Keywords: impaired kidney function, type 2 diabetes, kidney disease, sub-saharan africa, diabetic kidney disease
inTrODUcTiOn
Non-communicable diseases (NCD), such as diabetes and kidney disease, have replaced com-
municable diseases as the most common causes of premature death worldwide. An estimated 
80% of the NCD burden occurs in low- or middle-income countries (1). Diabetes is an important 
risk factor for kidney disease; about a third to half of the individuals with diabetes develop kidney 
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disease (2, 3). Globally, while the age-standardized rates for 
chronic kidney disease (CKD) due to hypertension decreased 
by 22.4%, the rates for CKD due to diabetes mellitus increased 
by 10.6%, between 1990 and 2013 (4). In all developed and many 
developing countries, diabetes and hypertension are the lead-
ing causes of CKD (5). Given the projection that the number of 
people with diabetes in sub-Saharan Africa (SSA) will increase 
by 141% from 14.2 million in 2015 to 34.2 million in 2040 (6), 
the potential for an increasing burden of kidney disease in SSA 
is high.
There is a dearth of data on the risk of impaired kidney func-
tion among individuals with type 2 diabetes (T2D) in SSA. The 
studies from SSA that have reported on the prevalence of kidney 
disease often had characteristics that limit their interpretation, 
including lack of standard definitions of kidney disease and 
small sample size of typically <1000 adults (7–18). The objec-
tive of this study was to examine the association between T2D 
and impaired kidney function, an indicator of CKD, in a large 
sample of about 5000 sub-Saharan Africans and to examine the 
variation of the association between T2D and risk of impaired 
kidney function by age, hypertension, body mass index (BMI), 
and dyslipidemia.
MaTerials anD MeThODs
study Population
The study participants were adults who were at least 18  years 
old. Individuals with T2D were enrolled from university medi-
cal centers in Ibadan, Enugu, and Lagos in Nigeria, Accra, and 
Kumasi in Ghana and Eldoret in Kenya as part of a genetic 
epidemiology study of T2D in sub-Saharan Africans. Individuals 
without T2D were enrolled from surrounding communities of 
the respective university medical centers. At each site, research 
nurses approached potential participants at outpatient clinics and 
community centers, discussed the study objectives, and obtained 
informed consent from willing participants. About 96% of those 
who were approached agreed to participate in the study. After 
providing informed consent, all participants provided informa-
tion on demography, social, and lifestyle factors, and underwent 
a clinical examination that included a medical history, clinical 
anthropometry, blood pressure measurements, and blood 
sampling for measurement of cardiometabolic parameters. 
Weight was measured in light clothes on an electronic scale to 
the nearest 0.1 kg, and height was measured with a stadiometer 
to the nearest 0.1 cm. BMI was computed as weight in kilograms 
divided by the square of the height in meters. Ethical approval 
for this study was granted by the Institutional Review Board at 
each study site, Howard University and the National Institutes 
of Health.
ascertainment of Type 2 Diabetes
The definition of T2D was based on the following criteria: a fast-
ing plasma glucose concentration ≥126 mg/dl (7.0 mmol/l) or a 
2-h post-load value in the oral glucose tolerance test ≥200 mg/
dl (11.1  mmol/l) on more than one occasion. Alternatively, 
a diagnosis of T2D was accepted if an individual was on 
pharmacological treatment for T2D and review of clinical 
records indicated adequate justification for that therapy. The 
detection of autoantibodies to glutamic acid decarboxylase 
and/or a fasting C-peptide ≤0.03  nmol/l was used to exclude 
probable cases of type 1 diabetes. Participants without T2D were 
those who had FPG <100 mg/dl (5.6 mmol/l) or 2-h post-load 
of <140  mg/dl (7.8  mmol/l) and no symptoms suggestive of 
diabetes (the classical symptoms being polyuria, polydipsia, and 
unexplained weight loss).
ascertainment of Kidney Function
Serum creatinine levels were determined using a Jaffe reaction 
without deproteinization on a COBAS Integra 400 analyzer 
(Roche Diagnostics, IN, USA). Currently, glomerular filtration 
rate (GFR) is considered to be the best indicator of renal function 
(19). Given that results from studies evaluating the performance 
of estimated GFR (eGFR) equations in black Africans have been 
inconsistent (20, 21), we calculated race and gender-specific 
eGFR using the Modification of Diet in Renal Disease (MDRD) 
and Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equations. A recent evaluation of eGFR equations 
among Africans with T2D showed that the MDRD was associated 
with lower bias compared to the CKD-EPI and Cockcroft–Gault 
equations (22). Thus, we used eGFR calculated from the MDRD 
equation for our multivariate analyses. We defined impaired kid-
ney function as a dichotomous trait based on an eGFR <60 ml/
min/1.73  m2, which corresponds to CKD stage 3 or worse 
based on the new Kidney Disease Improving Global Outcomes 
(KDIGO) staging recommendations (23), when accompanied 
by signs of kidney damage. Cases were defined as individuals 
with impaired kidney function (eGFR <  60  ml/min/1.73  m2) 
and controls as individuals without impaired kidney function 
(eGFR ≥ 60 ml/min/1.73 m2).
statistical analyses
Means and proportions of the participants’ baseline character-
istics were calculated. Tests of significance to compare means 
and proportions between participants with diabetes and those 
without diabetes were conducted using t-tests, Fisher’s exact, 
and Mantel–Haenszel tests. To examine the association between 
impaired kidney function (eGFR < 60 ml/min/1.73 m2) and T2D, 
logistic regression models were used to estimate odds ratios (OR) 
and 95% confidence intervals (CI). Multivariate models were 
adjusted for age, sex, BMI, hypertension, high-density lipopro-
tein cholesterol (HDLc), low-density lipoprotein cholesterol 
(LDLc), and triglycerides. Hosmer and Lemeshow goodness-of-
fit test was used to examine whether the model was a good fit. To 
examine potential effect modification of the association between 
T2D and risk of impaired kidney function, multivariate models 
were stratified on age (<60 vs. ≥60 years), sex (male vs. female), 
BMI [normal (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2), 
obese (≥30 kg/m2)], hypertension (yes vs. no), HDLc (<1.04 vs. 
≥1.04 mmol/l), LDLc (<4.14 vs. ≥4.14 mmol/l), and triglycer-
ides (<2.26 vs. 2.26 mmol/l). All p values are two-sided, and the 
analyses were conducted using SAS 9.3 for Unix (SAS Institute 
Inc., Cary, NC, USA).
TaBle 2 | characteristics of the study participants by type 2 diabetes 
status.
characteristic Type 2 diabetes status p-value
Type 2 diabetes non-type 2 
diabetes
n 2208 2607
Age, years 55 ± 11 42 ± 15.3 <0.01
Male sex, % 40 42 0.04
Body mass index, kg/m2 26.9 ± 5.4 25.5 ± 5.7 <0.01
Smoking, % <0.01
Current 3 5
Former 15 9
Never 82 86
Hypertension, % 68.3 35.3 <0.01
Albumin, g/l 44 ± 8 44 ± 6 0.37
Creatinine, μmol/l 88.4 ± 44.2 79.6 ± 17.7 <0.01
eGFR (MDRD), ml/
min/1.73 m2
95.3 ± 36.6 108.1 ± 36.6 <0.01
eGFR (CKD-EPI), ml/
min/1.73 m2
89.8 ± 27.6 105.1 ± 27.7 <0.01
Impaired kidney function, % 13.4 4.8 <0.01
HDL, mmol/l 1.2 ± 0.5 1.22 ± 0.4 <0.01
LDL, mmol/l 3.5 ± 1.3 3.19 ± 1.2 <0.01
Triglyceride, mmol/l 1.4 ± 0.9 1.1 ± 0.6 <0.01
Values are means ± SD or percentages.
TaBle 1 | characteristics of the study participants by case–control 
status.
impaired kidney function, egFr (MDrD) p-value
cases  
(<60 ml/min/1.73 m2)
controls  
(≥60 ml/min/1.73 m2)
n 421 4394
Age, years 58.7 ± 10.4 47 ± 14 <0.01
Male sex, % 37 63 0.08
Body mass index, 
kg/m2
26.6 ± 4.8 26.1 ± 5.7 0.12
Smoking, % <0.01
Current 2 4
Former 14 12
Never 84 84
Type 2 diabetes, % 70.1 43.5 <0.01
Hypertension, % 73.5 48.2 <0.01
Albumin, g/l 53 ± 13 43 ± 6 <0.01
Creatinine, μmol/l 150.1 ± 70.7 70.7 ± 17.6 <0.01
eGFR (MDRD), ml/
min/1.73 m2
48.0 ± 10.7 107.4 ± 34.5 <0.01
eGFR (CKD-EPI), ml/
min/1.73 m2
45.5 ± 10.7 103.0 ± 24.5 <0.01
HDL, mmol/l 1.3 ± 0.6 1.2 ± 0.4 <0.01
LDL, mmol/l 4.4 ± 1.6 3.2 ± 1.1 <0.01
Triglyceride, mmol/l 1.7 ± 0.7 1.1 ± 0.7 <0.01
Values are means ± SD or percentages.
3
Adebamowo et al. Diabetes and Impaired Kidney Function
Frontiers in Endocrinology | www.frontiersin.org May 2016 | Volume 7 | Article 50
resUlTs
The baseline characteristics of the study participants are presented 
in Table 1. A total of 4815 participants (421 cases and 4394 controls) 
were included in the analyses. The mean age (SD) was 48 (15) years, 
and 41% (1984/4815) were male. Participants with impaired kid-
ney function were more likely to be older, female, hypertensive, and 
diabetic, and have higher levels of LDL and triglycerides (Table 1).
Using the CKD-EPI equation, the mean (SD) eGFR for those 
with T2D was 90 (28) ml/min/1.73 m2 compared to those without 
T2D, 105 (28) ml/min/1.73  m2, p-value <0.001. Based on the 
CKD-EPI equation, 16.3% of those with T2D and 5.5% of those 
without T2D had impaired kidney function, p-value <0.001. 
Using the MDRD equation, the mean (SD) eGFR for those with 
T2D was 95 (37) ml/min/1.73  m2 compared to those without 
T2D, 108 (37) ml/min/1.73  m2, p-value <0.001. Based on the 
MDRD equation, 13.4% of those with T2D and 4.8% of those 
without T2D had impaired kidney function, p-value <0.001. The 
distribution of the characteristics of the study participants by 
T2D is shown in Table 2. Further analyses were conducted using 
estimates derived from the MDRD equation.
In multivariate analyses adjusted for age, sex, BMI, and 
hypertension, those with T2D had higher risk of impaired kidney 
function [OR 1.68 (95% CI 1.33–2.12), p-value <0.001], com-
pared to those without T2D (Table 3). With further adjustment 
of the models for lipids (HDLc, LDLc, and triglycerides) in the 
final model, the risk of impaired kidney function among those 
with T2D remained significant [OR 1.50 (95% CI 1.17–1.91), 
p-value = 0.001]. The goodness-of-fit test p-value was 0.85, sug-
gesting that the final model had a good fit.
Next, we conducted stratified analysis to determine any poten-
tial effect modification by age, sex, BMI, hypertension, HDLc, 
LDLc, and triglycerides (Table 4). We observed that participants 
with T2D had higher risk of impaired kidney function com-
pared to those without T2D, regardless of stratification factors. 
Furthermore, participants with T2D who were at least 60 years 
old, female, obese, or hypertensive had higher risk of impaired 
kidney function compared to those who were not. Participants 
with T2D had significantly higher risk of impaired kidney func-
tion if they had HDLc levels <1.04 mmol/l [OR 1.83 (1.22–2.73), 
p-interaction = 0.005] compared to those without T2D.
DiscUssiOn
Type 2 diabetes is a known risk factor for CKD; however, there 
are limited data from SSA on this important relationship. In this 
study of impaired kidney function in relation to T2D in SSA, about 
8.7% of the study participants had impaired kidney function with 
a higher prevalence in T2D compared to controls (13.4% of those 
with T2D and 4.8% of those without T2D). Individuals with T2D 
had 50% significantly increased risk of impaired kidney function 
after adjustment for covariates, compared to those without T2D. 
To our knowledge, this is the largest single study of T2D and 
impaired kidney function in SSA to date.
Although GFR has been established as the most useful over-
all index of kidney function, proteinuria, an easily measured 
indicator of glomerular disease, is still used to ascertain acute 
and CKD in many studies. Many studies from SSA have used 
proteinuria and/or eGFR measured at one time point as diag-
nostic criteria for CKD. While measurement of urinary protein 
has been the most commonly used method in African studies 
(10), the cutoff for defining kidney impairment has varied 
between studies, including ≥20  mg/dl (16, 24) or ≥30  mg/dl 
(8, 12) of protein in urine. A  recent systematic review and 
TaBle 4 | association (odds ratios and 95% ci) between type 2 diabetes 
and impaired kidney function, stratified by key risk factors.
egFr cases  
(<60 ml/min/1.73 m2)
controls  
(≥60 ml/min/1.73 m2)
p for 
interaction
Age
<60 years 1.57 (1.15–2.13) Ref (1.00) 0.73
≥60 years 2.23 (1.47–3.36) Ref (1.00)
Sex 0.88
Male 1.36 (0.92–2.00) Ref (1.00)
Female 1.68 (1.23–2.30) Ref (1.00)
Body mass index 0.28
Normal 1.51 (1.02–2.22) Ref (1.00)
Overweight 1.23 (0.82–1.85) Ref (1.00)
Obese 1.93 (1.14–3.27) Ref (1.00)
Hypertension 0.17
No 1.23 (0.81–1.86) Ref (1.00)
Yes 1.71 (1.26–2.32) Ref (1.00)
HDLc  < 0.01
<1.04 mmol/l 1.83 (1.22–2.73) Ref (1.00)
≥1.04 mmol/l 1.40 (1.04–1.88) Ref (1.00)
LDLc 0.50
<4.14 mmol/l 1.87 (1.35–2.61) Ref (1.00)
≥4.14 mmol/l 1.27 (0.89–1.80) Ref (1.00)
Triglycerides 0.54
<2.26 mmol/l 1.52 (1.17–1.96) Ref (1.00)
≥2.26 mmol/l 2.69 (1.24–5.87) Ref (1.00)
GFR was estimated using the MDRD equation.
Logistic regression models were used to estimate the odds ratios and 95% confidence 
intervals.
Each model was adjusted for age, sex, body mass index, hypertension, HDL, LDL, and 
triglyceride.
TaBle 3 | association (odds ratios and 95% ci) between type 2 diabetes and impaired kidney function.
Models impaired kidney function, egFr (MDrD) p-value goodness-of-fit  
p-value
cases (<60 ml/min/1.73 m2) controls (≥60 ml/min/1.73 m2)
Age-adjusted model 1.83 (1.45–2.29) Ref (1.00) <0.001 0.001
Multivariate model 1 1.70 (1.35–2.15) Ref (1.00) <0.001 0.004
Multivariate model 2 1.68 (1.33–2.12) Ref (1.00) <0.001 0.06
Multivariate model 3 1.50 (1.17–1.91) Ref (1.00) 0.001 0.85
GFR was estimated using the MDRD equation.
Logistic regression models were used to estimate the odds ratios and 95% confidence intervals.
Goodness of model fit was conducted with Hosmer and Lemeshow goodness-of-fit test.
Multivariate model 1 = age, sex, and hypertension.
Multivariate model 2 = model 1 + body mass index.
Multivariate model 3 = model 2 + lipids (high-, low-density lipoprotein, triglyceride).
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meta-analysis, including 90 studies from 96 sites in SSA reported 
that the overall prevalence of CKD in SSA was 13.9% (95% CI 
12.2–15.7), the prevalence of CKD varied widely, from as low 
as 2% in Côte d’Ivoire to as high as 30% in Zimbabwe (10). In 
the systematic review, several terms were regarded as equiva-
lent to CKD, including renal impairment, renal insufficiency, 
proteinuria, nephropathy, and end-stage renal disease. The wide 
variation in the prevalence estimates may be due to differences 
in study ascertainment criteria, measurement methods, and 
definitions of CKD. Other implicated causes of CKD in SSA 
that may explain the geographical variation of CKD prevalence 
include HIV infection, use of traditional medication or herbal 
formulations, and chronic glomerulonephritis.
The few studies carried out to examine the burden of kidney 
impairment defined by GFR among T2D in SSA have been limited 
by their small sample size and design. A cross-sectional study 
of 369 participants (94% had T2D) in Mwanza, Tanzania (15) 
showed that ~25% of the study participants had eGFR <60 ml/
min/1.73 m2. A review of data from 98 medical records showed 
that the prevalence of kidney impairment, defined as eGFR 
<90 ml/min/1.73 m2 was 18.1% among T2D in the Democratic 
Republic of Congo (25). In Nigeria, data from a retrospective 
sample of 628 patients who were referred to an outpatient clinic 
with diagnosis of hypertension, diabetes, or both, reported that 
38.5% of the patients had eGFR ≤60 ml/min/1.73 m2 (14). The 
present study was larger, including about 5000 participants with 
prospectively collected data and provided risk estimates using a 
case–control approach.
Many factors contribute to the risk of impaired kidney func-
tion in T2D. In the present study, we observed that individuals 
with both T2D and hypertension had increased risk of impaired 
kidney function compared to those with T2D alone. The 
prevalence of hypertension among T2D participants was 68% 
in this study. A previous study reported that the prevalence of 
hypertension among patients with diabetes was as high as 79% 
(26). Similar to our findings, older age, obesity, and dyslipidemia 
have been reported as probable risk factors for impaired kidney 
function in T2D (27). It has been suggested that these risk factors 
lead to oxidative stress and inflammation, which promote cellular 
proliferation of endothelial, epithelial, or mesangial cells, result-
ing in congestion, leukocyte infiltration, glomerular membrane 
thickening, hyalinization and sclerosis, deposition of fibrin indi-
cating blood leakage, or intra-glomerular thrombosis (28). These 
changes lead to tissue hypoxia, tissue damage (29) and decline in 
GFR. In particular, obesity and dyslipidemia may contribute to 
kidney disease by establishing low-grade inflammation through 
high expression of lipogenic and pro-inflammatory genes (30). 
Genetic risk factors also contribute to impaired kidney function. 
Of particular relevance to our study population is the apolipopro-
tein L1 (APOL1) gene that has been identified as a risk locus for 
kidney disease in populations of African ancestry, having been 
first identified in African Americans and subsequently confirmed 
in studies of sub-Saharan Africans, including Nigerians (31).
This study has several notable strengths, including being the 
largest single study of impaired kidney function and T2D in 
SSA thus far, to our knowledge. Importantly, this study provides 
African risk estimates of impaired kidney function in T2D. Other 
strengths of the study include adjusting for several lifestyle and 
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biochemical factors known to affect the risk of impaired kidney 
function, and using standardized tests and validated protocols. 
Our study has some important limitations. The availability of data 
on proteinuria on the study participants would have facilitated 
more fine-grained delineation of kidney damage. Thus, some 
participants with eGFR above 60  ml/min/1.73  m2 and clinical 
signs of nephropathy may have been misclassified. Also, we did 
not have data on other implicated causes of kidney impairment 
in SSA, such as infections, use of traditional medication or 
herbal formulations and medications, and were unable to assess 
the impact of these factors on the relationship between T2D and 
kidney impairment in the sample population. Due to the case–
control design of this study, we did not have longitudinal data 
and also could not rule out the possibility of bias from residual 
confounding because of unmeasured factors. The associations 
derived may not infer causality. Large-scale longitudinal studies 
to determine the incidence, predictors, and genetic risk factors of 
kidney disease are warranted in African populations, especially 
among individuals with T2D.
cOnclUsiOn
In conclusion, our study provides evidence for a notable burden 
of impaired kidney function among T2D in SSA, especially 
among individuals with dyslipidemia. Given that individuals with 
T2D often have comorbidities, such as hypertension, obesity, and 
dyslipidemia, screening for renal impairment should be a priority 
in the course of their clinical management. Implementation of 
preventive strategies, early diagnosis and treatment of T2D across 
SSA populations would facilitate a reduction in the clinical and 
public health burden of T2D and its comorbidities, including 
T2D-associated renal impairment.
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